Chemotherapy Associated Acute Respiratory Failure: a Child With Relapsed Langerhans Cell Histiocytosis

Number: 2 June 1, 2020
  • Hadi Geylan
  • Kamuran Karaman
  • Mecnun Çetin
  • Akkız Şahin Yaşar
EN TR

Chemotherapy Associated Acute Respiratory Failure: a Child With Relapsed Langerhans Cell Histiocytosis

Abstract

Langerhans cell histiocytosis LHH ; is a clonal neoplastic proliferation of Langerhans-type cells with expressing CD1a, langerin and S100 protein and presence of Birbeck granules in the ultrastructural examination. Clinical manifestations are very variable. The bone, bone marrow, skin, lymph nodes, lung, liver, spleen and meninges are most involved. Most cases are diagnosed during childhood and the annual incidence is approximately 5 million. The agent should be selected with the least side effect according to the number of lesions and the area of invasion. Most patients respond to initial treatment. In the last 3.5 years, with the diagnosis of LHH, approximately two years after the end of chemotherapy, the patient referred to our hospital with a central diabetes insipidus. Relapse Langerhans cell histiocytosis was diagnosed as a result of imaging studies. Chemotherapy protocol with cladribine and cytarabine was started for the patient. After the third session/round/cycle of the treatment, pneumonia accompanied by rapid onset of respiratory distress developed after the febrile neutropenia recovered. Here we present a case of sudden respiratory insufficiency after cladribine and/or cytarabine chemotherapy and a dramatic response to steroid treatment

Keywords

References

  1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008.
  2. Pileri SA, Grogan TM, Harris NL, Banks P, Campo E, Chan JK, et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology 2002;41:1–29. [CrossRef]
  3. Arico M, Girschikofsky M, Genereau T, Klersy C, McClain K, Grois N, et al. Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. Eur J Cancer 2003;39:2341–8. [CrossRef]
  4. Minkov M, Prosch H, Steiner M, Grois N, Potschger U, Kaatsch P, et al. Langerhans cell histiocytosis in neonates. Pediatr Blood Cancer 2005;45:802–7. [CrossRef]
  5. McClain KL. Treatment of langerhans cell histiocytosis. UpToDate. Waltham, MA 2013. https://www.uptodate.com/contents/ treatment-of-langerhans-cell-histiocytosis
  6. Kairouz S, Hashash J, Kabbara W, Mchayleh W, Tabbara IA. Dendritic cell neoplasms: An overview. Am J Hematol 2007;82:924–8. [CrossRef]
  7. Motomura S, Fujisawa S, Fujimaki K, Mohri H, Okubo T. Interstitial pneumonia induced by combination therapy with low‐dose cytarabine and granulocyte colony‐stimulating factor. Am J Hematol 1995;49:364. [CrossRef]
  8. Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res 2012;13:39. [CrossRef]

Details

Primary Language

Turkish

Subjects

-

Journal Section

-

Authors

Hadi Geylan

Kamuran Karaman

Mecnun Çetin

Akkız Şahin Yaşar

Publication Date

June 1, 2020

Submission Date

-

Acceptance Date

-

Published in Issue

Year 1970 Number: 2

EndNote
Geylan H, Karaman K, Çetin M, Yaşar AŞ (June 1, 2020) Kemoterapi İlişkili Akut Solunum Yetmezliği: Relaps Langerhans Hücreli Histiositozlu Bir Çocuk. Acıbadem Üniversitesi Sağlık Bilimleri Dergisi 2 350–353.